[{"id":"4bbdcbf6-ccbf-4476-adeb-a48a0a44206f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05225363","created_at":"2022-02-05T18:29:53.670Z","updated_at":"2024-07-02T16:35:01.290Z","phase":"Phase 1","brief_title":"Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer","source_id_and_acronym":"NCT05225363","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD8 • PD-1 • LAG3 • PTPRC • CCR7 • CD27 • LAMP1","pipe":" | ","alterations":" HRD • BRCA mutation","tags":["CD8 • PD-1 • LAG3 • PTPRC • CCR7 • CD27 • LAMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TAG72-CAR T"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 05/05/2022","start_date":" 05/05/2022","primary_txt":" Primary completion: 04/05/2026","primary_completion_date":" 04/05/2026","study_txt":" Completion: 04/05/2027","study_completion_date":" 04/05/2027","last_update_posted":"2024-05-23"}]